Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

Diseases and Conditions Researched

Addiction

What is the purpose of this trial?

Specific Aim #1: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in reducing cocaine use as measured by cocaine urine results and self-report days of use.

Specific Aim # 2: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in improving attention, assessed with the Rapid Visual Information Processing (RVIP) and the Simple Reaction Time (SRT) tests Specific Aim # 3: To determine if improvement in attention during the first four weeks of treatment will mediate galantamine's efficacy in reducing cocaine use.


Participation Guidelines

Age: 18 Years - 60 Years
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: National Institute on Drug Abuse
Dates:
Last Updated:
Study HIC#: 1007007119